Published in AIDS Weekly, September 18th, 2000
The vaccine is the first specifically designed to combat the Clade A HIV-1 virus, the most prevalent strain in many parts of Africa.
Eighteen people volunteered to receive injections of the vaccine at Churchill Hospital in Oxford, England. If the tests are successful, trials will begin in Nairobi, Kenya, within six months, according to the Medical Research Council, a U.K. government-funded national research organization.
The hope is that the vaccine will stimulate the body to produce killer T cells that will destroy HIV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.